|
Synonyms: AGN-150998 | MP0112
Compound class:
Peptide or derivative
Comment: Abicipar pegol is a VEGFA targeting protein conjugate generated using DARPin® technology [1,3]. The INN record for this construct describes it as a 'pegylated composite protein for clinical applications (CPCA)'. The amino acid sequence for the protein component is provided here. Structurally, the conjugate contains glycyl-seryl-ankyrin repeats (3-35, 36-68, 69-101, 102-123) with a short linker (127-134) and a cysteine di-sulphide bond (1-135), conjugated via a maleimide group linker (thioether bond to C135) to a single linear methoxy polyethylene glycol 20 (mPEG20). DARPins are protein therapeutics that are being developed as an alternative to antigen receptors (antibodies).
|
| References |
|
1. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A. (2003)
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol, 332 (2): 489-503. [PMID:12948497] |
|
2. Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, Hepp J, Stumpp MT. (2013)
Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol, 155 (4): 697-704, 704.e1-2. [PMID:23218689] |
|
3. Stumpp MT, Binz HK, Amstutz P. (2008)
DARPins: a new generation of protein therapeutics. Drug Discov Today, 13 (15-16): 695-701. [PMID:18621567] |
